Medical devices, healthcare technology and the business of care
PMA approval · P250017

GORE VIABAHN FORTEGRA Venous Stent

W. L. Gore & Associates, Inc. · Decision date Dec 19, 2025

FDA DECISIONP250017

What did the FDA approve?

FDA records P250017 as an original PMA application. The recorded decision is approval, dated Dec 19, 2025.

FDA approval order statement

The GORE VIABAHN FORTEGRA Venous Stent is indicated for use in the treatment of symptomatic inferior vena cava obstruction with or without combined iliofemoral obstruction.
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Dec 19, 2025

FDA source record

Regulatory record facts

Identifier
P250017
Regulatory pathway
Premarket approval application
Product code
QTL
Decision code
APPR
Decision date
Dec 19, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stent, vena cava.

Product code
QTL
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P250017 received

    Application receipt date recorded by FDA.

  2. P250017 · FDA decision

    APPR

  3. P250017/S002 · Related supplement

    GORE VIABAHN FORTEGRA Venous Stent

  4. P250017/S001 · Related supplement

    GORE VIABAHN FORTEGRA Venous Stent

  5. P250017/S003 · Related supplement

    GORE VIABAHN FORTEGRA Venous Stent

Timeline entries are records held by MedtechLedger for P250017. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250017

Product / regulatory recordCompanyPathwayDecision dateSource
W. L. Gore & Associates, Inc.PMA supplementMar 6, 2026FDA
W. L. Gore & Associates, Inc.PMA supplementApr 7, 2026FDA
W. L. Gore & Associates, Inc.PMA supplementApr 30, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

W. L. Gore & Associates, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1505 N Fourth St., Flagstaff, AZ, 86004

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records